Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First

Executive Summary

Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.

Related Content

FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
FTC K-Dur Case Nears Trial: WLF Says Agency Is Challenging Judiciary
AHP Exiting Oral Generics Business; K-Dur Settlement With FTC Near
Upsher Launches K-Dur Generic With Exclusivity; FTC Hearing In December
Andrx/Aventis Cardizem CD Class Action Appeal Pending; State AGs Sue
HHS Will Study Generic Approval Process; McCain Sets Hearing For May 17
GPhA Waxman/Hatch Plan Would Use Bonds To Protect 180-Day Exclusivity
Andrx/Aventis Settle With FTC: Agency Says Cardizem CD Generic Not Delayed
Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts